Immunisation and cancer screening entry points

Australian National Immunisation Program & Cancer Screening Programs

Preventive medicine and population screening form the backbone of primary healthcare in Australia. Medical practitioners must demonstrate mastery of the Australian National Immunisation Program (NIP) schedule, organized population cancer screening algorithms, and absolute cardiovascular disease risk assessment to optimize health outcomes and prevent premature morbidity and mortality.

---

The Australian National Immunisation Program (NIP) Schedule

The National Immunisation Program (NIP), funded by the Commonwealth and State/Territory governments, provides free vaccines to eligible Australians across defined life stages. Vaccinations must be registered promptly on the Australian Immunisation Register (AIR).

Clinical Nuances of Childhood Immunisation

• Hepatitis B at Birth: Administered within 24 hours of birth to prevent perinatal mother-to-child transmission. If the mother is hepatitis B surface antigen (HBsAg) positive, the neonate must receive both the hepatitis B vaccine and Hepatitis B Immunoglobulin (HBIG) within 12 hours of birth in separate anatomical limbs.
• Rotavirus Vaccine Safety: Live-attenuated oral vaccine with strict age boundaries to minimize the rare risk of intussusception. The first dose must be given between 6 weeks and 14 weeks and 6 days of age; the final dose must be completed by 24 weeks and 6 days of age. Never initiate rotavirus vaccination in infants aged 15 weeks or older.
• MMR vs MMRV: The combination MMRV (measles-mumps-rubella-varicella) vaccine carries a higher rate of post-vaccination febrile convulsions if given as the first measles-containing dose. Therefore, MMR is given at 12 months, and MMRV is reserved for 18 months.

Adolescent School-Based Immunisation Programs

• Year 7 (Aged 12 to 13 years):
  • Human Papillomavirus (9vHPV - Gardasil 9): Administered as a single dose in the national school program for immunocompetent adolescents. Australia transitioned from a two-dose to a single-dose schedule based on robust global evidence demonstrating equivalent long-term protection against high-risk oncogenic HPV types (16, 18, 31, 33, 45, 52, 58) and anogenital wart types (6, 11). Immunocompromised individuals still require a 3-dose schedule.
  • dTpa Booster: Reduced-antigen diphtheria-tetanus-acellular pertussis booster.
• Year 10 (Aged 15 to 16 years):
  • Meningococcal ACWY (MenACWY): Quadrivalent conjugate booster targeting high-carriage adolescent cohorts to induce herd immunity.

Maternal Immunisation in Pregnancy

Maternal vaccination provides dual protection by preventing severe maternal morbidity and conferring passive protection to the neonate via transplacental IgG antibodies before the infant can be immunized:

• dTpa (Pertussis-containing vaccine): Recommended and funded for administration between 20 and 32 weeks of gestation during EVERY pregnancy, regardless of the interval since a previous dose. Receiving the vaccine during this window maximizes maternal antibody production and transplacental transfer.
• Influenza Vaccine: Inactivated influenza vaccine is recommended and funded at any stage (trimester) of pregnancy, providing protection during maternal gestation and reducing infant influenza hospitalisation during the first 6 months of life.
• Respiratory Syncytial Virus (RSV) Vaccine: Recombinant RSV prefusion F protein vaccine (Abrysvo) administered between 28 and 36 weeks of pregnancy to protect infants from severe lower respiratory tract illness (bronchiolitis and pneumonia).

Adult and risk-based immunisation

From July 2026, adult NIP pneumococcal vaccination uses 21vPCV (Capvaxive), replacing Prevenar 13 and Pneumovax 23 on the adult NIP. It is funded from 65 for non-Indigenous adults, 25 for First Nations adults and 18 for specified risk conditions. After previous pneumococcal vaccination, generally wait at least twelve months. The childhood vaccine and schedule differ.

Shingrix is a two-dose recombinant zoster vaccine, funded from 65 years, from 50 for First Nations adults, and for specified high-risk immunocompromised adults from 18. Influenza is annual for funded groups; use the age-appropriate current-season formulation rather than an obsolete fixed valency. RSV vaccination and infant monoclonal-antibody protection have separate age/risk/funding pathways. Check the current Handbook and state program rather than treating TGA approval as automatic NIP funding.

Review catch-up, occupational exposure, pregnancy and immunocompromise. A severe allergic reaction to a previous dose/component is different from a mild cold or local soreness. Live vaccines have pregnancy/immunocompromise restrictions; inactivated products have different considerations. Document informed consent, batch/site, adverse events and AIR reporting under current requirements.

Check history before a vaccine decision

For an older adult, confirm previous doses, age, risk conditions and the current vaccine product rather than repeating an old schedule automatically. A TGA-approved product is not necessarily funded for every age group. Explain expected reactions and serious warning signs, document consent, product, batch and administration, and use the adverse-event reporting pathway when indicated. A missed childhood dose usually leads to catch-up planning rather than restarting every series.

Australia's Four Organised Population Cancer Screening Programs

Australia maintains four nationwide, evidence-based, government-funded population cancer screening programs designed to detect malignancies at early, curable stages.

Primary references (checked 7 October 2026): Current Immunisation Handbook; 2026 adult pneumococcal update; National lung screening.